



Shahab Asgharzadeh, MD  
Associate Professor of Pediatrics  
Children's Hospital Los Angeles  
Keck School of Medicine, USC

Shahab Asgharzadeh, MD, is Associate Professor of Pediatrics at USC/Norris Comprehensive Cancer Center and a pediatric hematologist-oncologist in the Cancer and Blood Disease Institute at CHLA, where he has been since 2001. He is the director of the Neuroblastoma Basic and Translational Program and member of the KSOM Cancer Center Tumor Microenvironment Program. He obtained his Bachelor's degree in Biomedical Engineering from Northwestern University in 1992 and medical degree from University of Illinois in 1996. He completed pediatric residency and a fellowship in clinical medical ethics at University of Chicago in 2000 and subsequently worked as a research associate professor in Bioinformatics at Northwestern University. He completed his training in pediatric hematology-oncology at CHLA in 2005 prior to joining the faculty of the USC.

Dr. Asgharzadeh is primarily a physician-scientist spending about 10% of his time performing clinical duties. He has been named Top Doctor by Pasadena Magazine, and was the recipient of 2014 Walter Laug Distinguished Teaching Award, and the 2016 Determination Award from the American Cancer Society.

His research laboratory is focused on understanding the role of the tumor microenvironment and developing novel immunotherapies for children with peripheral and central nervous system tumors, focusing on high-risk neuroblastomas, medulloblastomas, and other brain tumors. His group's first report of identification of inflammation in childhood neuroblastomas and medulloblastomas has helped to better understand the role of the immune system in biology of childhood tumors. His research has also led to the development of several novel assays to identify subtypes of neuroblastomas and medulloblastomas and predict outcome. His research is funded in part by the NIH, DOD, American Cancer Society, and innovation award from Alex's Lemonade Stand Foundation, as well as Soccer for Hope Foundation. He is a member of the NCI-sponsored Neuroblastoma Therapeutically Applicable Research to Generate Effective Treatments (Neuroblastoma TARGET) project and an active member of the Children's Oncology Group and serves on the COG Neuroblastoma Biology Committee. He is also the chair of the New Approaches to Neuroblastoma Therapy (NANT) consortium's biology and precision clinical trials.